Telmisartan reduces mortality and left ventricular hypertrophy with sympathoinhibition in rats with hypertension and heart failure

American Journal of Hypertension

Volumn 27, Issue 2, 2014, Pages 260-267

  Kishi, Takuya ^a   Hirooka, Yoshitaka ^a   Sunagawa, Kenji ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

ARB; blood pressure; brain; heart failure; hypertension; sy mpathetic nerve activity.

Indexed keywords

CANDESARTAN HEXETIL; NORADRENALIN; TELMISARTAN; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ANIMAL EXPERIMENT; ARTICLE; ASCITES; BODY WEIGHT; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; ECHOCARDIOGRAPHY; HEART FAILURE; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE SIZE; HEART RATE; HEART WEIGHT; HYPERTENSION; NONHUMAN; PLEURA EFFUSION; PRIORITY JOURNAL; RAT; STROKE PRONE SPONTANEOUSLY HYPERTENSIVE RAT; SURVIVAL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; URINARY EXCRETION;

ARB; BLOOD PRESSURE; BRAIN; HEART FAILURE; HYPERTENSION; SY MPATHETIC NERVE ACTIVITY.;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; BENZOATES; BIPHENYL COMPOUNDS; HEART FAILURE; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MEDULLA OBLONGATA; NOREPINEPHRINE; RATS; RATS, INBRED SHR; REACTIVE OXYGEN SPECIES; TETRAZOLES; VENTRICULAR FUNCTION, LEFT;

EID: 84891601593     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1093/ajh/hpt188     Document Type: Article

References (31)

1. Chobanian AV, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee the seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560-2572.
2. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewics K, Ruilope L, Runkiewicz A, Schmieder RE, Struijker Boudier HAJ, Zanchetti A. 2007 Guidelines for the management of arterial hypertension: ESH/ESC Task Force. J Hypertens 2007; 25:1105-1187.
3. Verdecchia P, Porcellati C, Reboldi G, Gattobigio R, Borgioni C, Pearson TA, Ambrosio G. Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension. Circulation 2001; 104:2039-2044.
4. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KKL the progression from hypertension to congestive heart failure. JAMA 1996; 275:1557-1562.
5. Yamazaki T, Komuro I, Kudoh S, Zou YZ, Shiojima I, Mizuno T, Takano H, Hiroi Y, Ueki K, Tobe K, Kadowaki T, Nagai R, Yazaki Y. Angiotensin-II partly mediates mechanical stress-induced cardiachypertrophy. Circ Res 1995; 77:258-265.
6. Kjeldsen SE, Dahlof B, Devereux RB, Julius S, Aurup P, Edelman J, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Snapinn S, Wedel H, Grp LS. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy-A Losartan Intervention For Endpoint Reduction (LIFE) substudy. JAMA 2002; 288:1491-1498.
7. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM; Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349:1893-1906.
8. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355:1582-1587.
9. Cohn JN, Tognoni G. A randomized trial of the angiotensin receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345:1667-1675.
10. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function taking angiotensinconverting enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362:767-771.
11. Cice G, Di Benedetto A, D'Isa S, D'Andrea A, Marcelli D, Gatti E, Calabrò R. Effects of telmisartan added to angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial. J Am Coll Cardiol 2010; 56:1701-1708.
12. Li L, Zhou N, Gong H, Wu J, Lin L, Komuro I, Ge J, Zou Y. Comparison of angiotensin II type 1-receptor blockers to regress pressure overload-induced cardiac hypertrophy in mice. Hypertens Res 2010; 33:1289-1297.
13. Mancia G, Schumacher H, Redon J, Verdecchia P, Schmieder R, Jennings G, Yusoff K, Ryden L, Liu GL, Teo K, Sleight P, Yusuf S. Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the ongoing telmisartan alone and in combination with ramipril global endpoint trial (ONTARGET). Circulation 2011; 124:1727-1736.
14. Campbell RT, Jhund PS, Castagno D, Hawkins NM, Petrie MC, McMurray JJ. What have we learned about patients with heart faiure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE?. J Am Coll Cardiol 2012; 60:2349-2356.
15. Triposkiadis F, Karayannis G, Giamouzis G, Skoularigis J, Louridas G, Butler J the sympathetic nervous system in heart failure: physiology, pathophysiology, and clinical implications. J Am Coll Cardiol 2009; 54:1747-1762.
16. Grassi G, Bolla G, Quarti-Trevano F, Arenare F, Brambilla G, Mancia G. Sympathetic activation in congestive heart failure: reproducibility of neuroadrenergic markers. Eur J Heart Fail 2008; 10:1186-1191.
17. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Rhythm Society ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society Circulation 2005; 112:e154-e235.
18. Kishi T, Hirooka Y, Kimura Y, Ito K, Shimokawa H, Takeshita A. Increased reactive oxygen species in rostral ventrolateral medulla contribute to neural mechanisms of hypertension in stroke-prone spontaneously hypertensive rats. Circulation 2004; 109:2357-2362.
19. Kishi T, Hirooka Y, Konno S, Ogawa K, Sunagawa K. Angiotensin II type 1 receptor-activated caspase-3 through ras/mitogen-activated protein kinase-extracellular signal-regulated kinase in the rostral ventrolateral medulla is involved in sympathoexcitation in stroke-prone spontaneously hypertensive rats. Hypertension 2010; 55:291-297.
20. Guggilam A, Patel KP, Haque M, Ebenezer PJ, Kapusta DR, Francis J. Cytokine blockade attenuates sympathoexcitation in heart failure: cross-talk between nNOS, AT-1R and cytolines in the hypothalamic paraventricular nucleus. Eur J Heart Fail 2008; 10:625-634.
21. Han Y, Shi Z, Zhang F, Yu Y, Zhong MK, Gao XY, Wang W, Zhu GQ. Reactive oxygen species in the paraventricular nucleus mediates the cardiac sympathetic afferent reflex in chronic heart failure rats. Eur J Heart Fail 2007; 9:967-973.
22. Zucker IH, Schultz HD, Patel KP, Wang W, Gao L. Regulation of central angiotensin type 1 receptors and sympathetic outflow in heart failure. Am J Physiol 2009; 297:H1557-H1566.
23. Hirooka Y, Sagara Y, Kishi T, Sunagawa K. Oxidative stress and central cardiovascular regulation-pathogenesis of hypertension and therapeutic aspects. Circ J 2010; 74:827-835.
24. Leenen FHH, Yuan B. Prevention of hypertension by irbesartan in Dahl S rats relates to central angiotensin II type 1 receptor blockade. Hypertension 2011; 37:981-984.
25. Kishi T, Hirooka Y, Sunagawa K. Sympathoinhibition by orally administered telmisartan through the blockade of AT1 receptor in rostral ventrolateral medulla of hypertensive rats. Hypertens Res 2012; 35:940-946.
26. Gohlke P, Weiss S, Jansen A, Wienen W, Stangier J, Rascher W, Culman J, Unger T. AT1 receptor antagonist telmisartan administered peripherally inhibits central responses to angiotensin II in conscious rats. J Pharmacol Exp Ther 2001; 298:62-70.
27. Guyenet PG the sympathetic control of blood pressure. Nat Rev Neurosci 2006; 7:335-346.
28. Zimmerman MC, Lazartigues E, Sharma RV, Davisson RL. Hypertension caused by angiotensin II infusion involves increased superoxide production in the central nervous system. Circ Res 2004; 95:210-216.
29. Kim-Mitsuyama S, Yamamoto E, Tanaka T, Zhan Y, Izumi Y, Izumiya Y, Ioroi T, Wanibuchi H, Iwao H. Critical role of angiotensin II in excess salt-induced brain oxidative stress of stroke-prone spontaneously hypertensive rats. Stroke 2005; 36:1077-1082.
30. Verdecchia P, Angeli F, Gentile G, Mazzotta G, Reboldi G. Telmisartan for the reduction of cardiovascular morbidity and mortality. Expert Rev Clin Pharmacol 2011; 4:151-161.
31. Gomez-Garre D, Gonzalez-Rubio ML, Munoz-Pacheco P, Caro-Vadillo A, Aragoncillo P, Fernandez-Cruz A. Rosuvastatin added to standard heart failure therapy improves cardiac remodeling in heart failure rats with preserved ejection fraction. Eur J Heart Fail 2010; 12:903-912.